Kinetics of B-Cell Responses to Live Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age

2017-01-17 06:21:26 | BioPortfolio


This pilot study will investigate the peak of the post-immunization B-cell responses following vaccination with live, attenuated influenza vaccine in healthy children 2 years of age from blood samples taken at designated time points before and after vaccination.


This is an exploratory study to determine the peripheral antibody secreting cell response during Days 5-13 after immunization with LAIV.

Investigators hoped to enroll 27 healthy children, 2 years of age who had not had any prior LAIV or TIV within the past 2 years. Due to low enrollment, the study was halted.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science




2008-2009 FluMist LAIV (Intranasal)




Stanford University

Results (where available)

View Results


Published on BioPortfolio: 2017-01-17T06:21:26-0500

Clinical Trials [1376 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Annual trial for registration influenza vaccine with the strain composition for season 2008/2009

Safety of Nasal Influenza Immunisation in Children With Asthma

A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. In the United ...

Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)

As yet we do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here we test the hypothesis that the T-bet expressing frac...

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult vo...

A Study to Evaluate the Immunogenicity Composed of Four Vaccine Strains in a Live Influenza Vaccine in Children

The primary objective of this study is to demonstrate the immunologic noninferiority of a separate vaccine to FluMist in children 2 to 17 years of age.

PubMed Articles [1928 Associated PubMed Articles listed on BioPortfolio]

Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets.

Currently, influenza vaccine manufacturers need to produce 1-5 x 107 PFU of each vaccine strain to fill one dose of the current live-attenuated-influenza-vaccine (LAIV). To make a single dose of inact...

Safety of Live Attenuated Influenza Vaccine in Children with Moderate-Severe Asthma.

Live attenuated influenza vaccine (LAIV) is recommended for annual influenza vaccination in children from age 2 years. However, some guidelines recommend against its use in children with asthma or rec...

Necrotizing tracheobronchitis causing airway obstruction complicated by pandemic 2009 H1N1 influenza: A case report.

Influenza is an infection caused by the influenza virus, and its symptoms are mostly mild and self-limiting. However, influenza can cause severe or fatal complications in high-risk patients. Although ...

Nontraditional Uses of Live Attenuated Influenza Vaccine: School-Located Influenza Vaccination.

Immunization against influenza continues to be the best method of preventing influenza infection in children, and additionally, indirectly helping to lower disease in adults, given the role of childre...

Influenza in patients with cancer after 2009 pandemic AH1N1: An 8-year follow-up study in Mexico.

Immunosupressed patients are at high risk of influenza-related complications. Influenza AH1N1 has been hypothesized to induce worse outcomes in patients with malignancies, but after the A(H1N1)pdm09 f...

Medical and Biotech [MESH] Definitions

Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.

Public Law No: 111-5, enacted February 2009, makes supplemental appropriations for job preservation and creation, infrastructure investment, energy efficiency and science, assistance to the unemployed, and State and local fiscal stabilization, for fiscal year ending September 30, 2009.

Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.

Infection of domestic and wild fowl and other BIRDS with INFLUENZA A VIRUS. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic POULTRY.

A nonlinear electrophoretic technique used to separate a variety of ionic compounds, ranging from small metal ions to large molecules like proteins. Unlike "linear" zone electrophoresis in which separating solute bands continually spread by diffusion or dispersion, isotachophoresis forms self-sharpening, adjacent zones of substantially pure solute whose concentrations often exceed several mgs/ml. In isotachophoresis a multianalyte sample is introduced between the leading electrolyte and the terminating electrolyte where the sample ions have lower electrophoretic mobilities than the leading ion but larger than the terminating ion. (From "Isotachophoresis" on the AES Web Site [Internet]. Madison, WI: The American Electrophoresis Society; c2000-2008 [cited 2009 Aug 20]. Available from

More From BioPortfolio on "Kinetics of B-Cell Responses to Live Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age"

Quick Search

Relevant Topic

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Searches Linking to this Trial